LAUSR

Results: Patient characteristics were as follows: median age (range), 68 (47-83); ECOG PS 0/1, 21/10; PMþve/-ve, 12/19; No. of prior chemotherapy regimens 1-2/ 3, 11/20; and absolute eosinophil count (AEC)< 150/ 150/ml, 14/17. Objective response rate and disease control rate were (RECIST ver. 1.1) 26% vs. 0% (odds ratio [OR], 3.76; P1⁄4 0.12) and 79% vs. 50% (OR, 3.58; P1⁄4 0.12) in the PM -ve group (Cohort A) and the PMþve group (Cohort B). On univariate analysis, the pts with poor PS, PMþve, and high AEC were significantly poor TTF; and poor PS and PMþve were significantly identified as prognostic factors of poor OS. On multivariate analysis, only PMþve was independent negative impact not only for TTF but also for OS. Median TTF and OS were 5.4 vs. 1.3 months (M) (adjusted hazard ratio [HR], 4.29; 95% CI, 1.60-11.5; P< 0.01) and 28.2 vs. 7.5 M (adjusted HR, 3.68; 95% CI, 1.25-10.8; P1⁄4 0.02) in Cohort A and Cohort B. Six-months TTF probabilities of 42% vs. 0% (P1⁄4 0.03) and one-year OS probabilities of 58% vs. 8% (P< 0.01) were observed in Cohort A compared to in Cohort B.